Good afternoon. I'm D. Lin from Mayo Clinic and I am here at IMS in Greece. And here I'm very honored to have presented on behalf of all the collaborators from the International Myeloma Foundation Immune Therapy Database some of the very early results with real-world application of Toclistimab that is now regulatory approved for patients with relapsed refractory multiple myeloma. So we have data collected or contributed from institutions really across US, Europe, and UK showing that amongst a hundred, a little over a hundred patients who were treated with Toclistimab in standard of care practice, close to 70% of these patients would not have met clinical trial eligibility criteria. So that would be for either having had prior therapies that were targeting BCMA or having had organ dysfunctions and other comorbidity issues. But despite that, it's very encouraging to see in the real world that for these patients, the initial safety signals in terms of the cytokine release syndrome, neurotoxicities, infections, all of those seems to be very comparable to what we've seen in a clinical trial and the initial response rates are also very, very comparable. So that's all very encouraging. And of course, we'll continue to have follow-up on these patients to see how they do over time with this treatment.
HealthTree • October 6, 2023